Novo-owned biotech continues progress

Earlier this year, Novo A/S invested a double-digit million euros sum in the promising German biotech and CRO Evotec. The company has gone from a net deficit to a net profit, while its revenue increased by one third in the first quarter. A Novo director is set to join the company's board of directors.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us free for 14 days

Try a trial subscription for free access to our quality journalism

Frontpage right now

MSD's Keytruda fejler i mavekræftstudie

Immunterapien Keytruda fra amerikanske Merck/MSD har ikke kunnet overgå kemoterapi i andenlinjebehandling af patienter med kræft i mave eller spiserør. Lægemidlet blev for få måneder siden godkendt i indikationen i tredje linje.

Latest Top picks in English

Related articles